Scarica l'app Stockscreener
4.87
1.31%
-0.085
Dopo l'orario di chiusura:
4.87
Precedente Chiudi:
$4.955
Aprire:
$5
Volume 24 ore:
265.42K
Relative Volume:
1.06
Capitalizzazione di mercato:
$111.08M
Reddito:
$155.00K
Utile/perdita netta:
$-30.01M
Rapporto P/E:
-3.2039
EPS:
-1.52
Flusso di cassa netto:
$-11.98M
1 W Prestazione:
-20.23%
1M Prestazione:
-4.31%
6M Prestazione:
-54.93%
1 anno Prestazione:
-34.01%
Intervallo 1D:
$4.81
$5.08
Intervallo di 1 settimana:
$4.81
$6.17
Portata 52W:
$4.78
$14.74
Inmune Bio Inc Stock (INMB) Company Profile
Nome
Inmune Bio Inc
Settore
Industria
Telefono
(858) 964-3720
Indirizzo
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Confronta INMB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| INMB | 4.87 | 111.08M | 155.00K | -30.01M | -11.98M | -1.52 |
| VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-05-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Reiterato | Maxim Group | Buy |
| 2021-04-21 | Iniziato | B. Riley Securities | Buy |
| 2021-01-22 | Reiterato | Maxim Group | Buy |
| 2020-09-01 | Iniziato | BTIG Research | Buy |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Inmune Bio Inc Borsa (INMB) Ultime notizie
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease - The Manila Times
Inmune Bio Emerges as Biotech Innovator in 2023 - TipRanks
Learn to Evaluate (INMB) using the Charts - Stock Traders Daily
INmune Bio, Inc. (NASDAQ:INMB) Q3 2024 Earnings Call Transcript - MSN
INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? - Simply Wall St
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) - Yahoo Finance UK
INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... - Yahoo Finance
Earnings call: INmune Bio Q3 2024 results show progress in clinical trials - Investing.com
Inmune Bio Reports Increased Losses Amid Financing Efforts - TipRanks
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update - The Manila Times
INmune Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
INmune Bio Q3 2024 Earnings Preview - MSN
Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Increases By 5.6% - MarketBeat
INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB - The Manila Times
Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares - Yahoo Finance
INmune Bio (INMB) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
INmune Bio Says XPro1595 Promotes Remyelination, Key for Central Nervous System Diseases - MarketWatch
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination - The Manila Times
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024 - The Manila Times
Insider Stock Buying Reaches US$951.2k On INmune Bio - Yahoo Finance
Alliance Global Partners Begins Coverage on INmune Bio (NASDAQ:INMB) - MarketBeat
Reviewing Windtree Therapeutics (NASDAQ:WINT) and INmune Bio (NASDAQ:INMB) - Defense World
(INMB) Technical Data - Stock Traders Daily
INmune Bio stock hits 52-week low at $4.8 amid market challenges - Investing.com
INmune Bio, Inc. (NASDAQ:INMB) Sees Large Decrease in Short Interest - MarketBeat
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit - The Manila Times
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs By GuruFocus - Investing.com Canada
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs - Yahoo Finance
Where are the Opportunities in (INMB) - Stock Traders Daily
Insider Buying: CFO and 10% Owner David Moss Acquires Shares of INmune Bio Inc (INMB) - GuruFocus.com
INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Buys 10,000 Shares - Defense World
Inmune Bio CFO buys $52,868 in company stock - Investing.com India
Inmune Bio CFO buys $52,868 in company stock By Investing.com - Investing.com South Africa
Analytical Overview: INmune Bio Inc (INMB)’s Ratios Tell a Financial Story - The Dwinnex
INmune Bio Inc [INMB] Investment Guide: What You Need to Know - Knox Daily
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease - The Manila Times
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal (NASDAQ:INMB) - Seeking Alpha
CVI Holdings LLC Purchases New Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
CVI Holdings LLC Takes $5.26 Million Position in INmune Bio, Inc. (NASDAQ:INMB) - MarketBeat
Raymond James Initiates Coverage of INmune Bio (INMB) with Outperform Recommendation - MSN
Achieve, INmune, Lenz stocks win bullish view from RayJay - Seeking Alpha
INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Raymond James - Defense World
INmune Bio reports progress in prostate cancer trial By Investing.com - Investing.com Australia
INmune Bio reports progress in prostate cancer trial - Investing.com
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort - The Manila Times
Inmune Bio Inc Azioni (INMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inmune Bio Inc Azioni (INMB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tesi Raymond Joseph | President and CEO |
Sep 12 '24 |
Buy |
6.38 |
15,380 |
98,048 |
1,554,106 |
| Moss David J | Chief Financial Officer |
Sep 12 '24 |
Buy |
6.38 |
7,690 |
49,024 |
1,275,869 |
| Juda Scott | Director |
Jun 25 '24 |
Buy |
7.27 |
5,000 |
36,350 |
71,603 |
4.27%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):